Market capitalization | $1.43b |
Enterprise Value | $1.08b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 17.53 |
P/S ratio (TTM) P/S ratio | 23.26 |
P/B ratio (TTM) P/B ratio | 4.05 |
Revenue growth (TTM) Revenue growth | 6.45% |
Revenue (TTM) Revenue | $61.44m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
9 Analysts have issued a Ocular Therapeutix Inc forecast:
9 Analysts have issued a Ocular Therapeutix Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 61 61 |
6%
6%
|
|
Gross Profit | 56 56 |
5%
5%
|
|
EBITDA | -137 -137 |
74%
74%
|
EBIT (Operating Income) EBIT | -141 -141 |
73%
73%
|
Net Profit | -174 -174 |
160%
160%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.
Head office | United States |
CEO | Pravin Dugel |
Employees | 267 |
Founded | 2006 |
Website | www.ocutx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.